1. For the 4-month period from May to August 2021, how many patients has your trust treated with the following anti-VEGF treatments:
a. Aflibercept
b. Bevacizumab
c. Brolucizumab
d. Dexamethasone
e. Fluocinolone acetonide
f. Ranibizumab
2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.
a. Aflibercept
b. Bevacizumab
c. Brolucizumab
d. Dexamethasone
e. Fluocinolone acetonide
f. Ranibizumab
3. Within your trust, how many intra-vitreal injections/implants of each following treatments have been used (for any eye condition) in the four-month period from May to August 2021:
a. Aflibercept
b. Bevacizumab
c. Brolucizumab
d. Dexamethasone
e. Ranibizumab
4. If your trust is able to identify intra-vitreal injections/implants by eye condition, please provide the number of injections/implants used in the four-month period from May to August 2021 for Wet Age Related Macular Degeneration (wAMD) ONLY
a. Aflibercept
b. Bevacizumab
c. Brolucizumab
d. Dexamethasone
e. Ranibizumab

Download response Anti-VEFG treatments for eye conditions. 221221.docx